SciSparc Ltd. (SPRC) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SciSparc Ltd., in collaboration with Clearmind Medicine Inc., has announced the publication of an international patent application for a novel MDMA-based treatment aimed at improving safety and efficacy in mental health and addiction therapies. Their combined approach seeks to address FDA concerns by integrating MDMA with N-Acylethanolamines, promising advancements in clinical treatments of mental disorders and addictions. SciSparc, a clinical-stage pharmaceutical company, continues to focus on cannabinoid-based pharmaceuticals, while Clearmind concentrates on psychedelic-derived therapeutics for underserved health problems.
For further insights into SPRC stock, check out TipRanks’ Stock Analysis page.